Pluristem Therapeutics (PSTI) Release: Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia
5/13/2013 9:34:49 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HAIFA, Israel, May 13, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today its PLacental eXpanded (PLX) cells tested in preclinical animal models of preeclampsia effectively improved several parameters of the disease. The study was conducted in collaboration with Brett Mitchel PhD, Associate Professor of Internal Medicine at the Cardiovascular Research Institute (CVRI) of the Texas A&M College of Medicine. Dr. Mitchel will present details of the study on May 30th at the Society for Gynecological Investigation Summit in Jerusalem.
Help employers find you! Check out all the jobs and post your resume.
comments powered by